The following article, makes reference to certain companies and their products and any opinions expressed should not be taken to be the views of Dystonia Europe or its members. The article are written by respected authors and are provided for the information of Dystonia Europe News readers.
The next-generation DBS technology is now available in a rechargeable option
Medtronic the world’s leading medical technology company today announced it received CE (Conformité Européenne) Mark for its Percept™ RC neurostimulator for deep brain stimulation (DBS). The smallest and thinnest device on the market1-4, Percept™ RC is the only rechargeable DBS system with BrainSense™ sensing technology5 to be launched in the European Union (EU).
“This development represents a critical step in our journey to transform Brain Modulation through sensing-enabled DBS,” said Amaza Reitmeier, Vice President and General Manager for Medtronic Brain Modulation. “We are excited about the potential of Percept™ RC to provide a comfortable, personalized DBS therapy to those living with Parkinson’s Disease, Essential Tremor and Primary Dystonia. Percept™ RC is also the only rechargeable neurostimulator approved to serve patients with Epilepsy.”
“In addition to being the smallest DBS device on the market, Percept™ RC combines proprietary battery technology with our brain-sensing technology. These innovations are the culmination of 30 years6 of investment in clinical trials and R&D to improve the experience of DBS patients,” said Domenico De Paolis, Vice President Neuromodulation International, which is part of the Neuroscience Portfolio at Medtronic.
Overdrive™ battery technology provides physicians with flexibility to adjust therapy without impacting battery capacity. With weekly charging, the device has greater than 99% battery capacity at 15 years7. What’s more, rapid recharging means that patients can charge under normal conditions (from 10% to 90% full) in less than an hour8.
The Percept™ family of devices also features Medtronic’s exclusive BrainSense™ technology, which enables physicians to track patient brain signals and correlate them with patient-recorded events, such as symptoms or side-effects associated with their disease, or the medications to treat it. Physicians can then tailor therapy to a patient’s evolving needs based on that information, rather than on clinical assessments and patient-reported data alone.
As well as proprietary battery technology, the Percept™ RC DBS system features several other innovative features:
Engineered for patient comfort, it’s the world’s smallest and thinnest dual-channel DBS device. Low-profile design allows for a deeper implant depth and minimal visibility of the device9.
The Percept™ family is the only DBS therapy with MR conditional labeling that allows for 3T and 1.5T full-body MRI scans (without having to turn off DBS therapy)10-13, providing patients access to cutting-edge medical imaging when they need it.
It’s designed to facilitate expanded capabilities, allowing the Percept™ RC devices of today to benefit from software updates of the future.
Percept™ RC is approved in the EU for the treatment of symptoms associated with Parkinson’s Disease (PD), Essential Tremor, Primary Dystonia, and Epilepsy.
The Percept™ RC neurostimulator will be available in Western Europe beginning mid-December, and will launch in additional regions based on local regulations.
Please read the full version here
